SARS-CoV-2 RT-PCR profile in 298 Indian COVID-19 patients: a retrospective observational study.


Journal

Pathogens and disease
ISSN: 2049-632X
Titre abrégé: Pathog Dis
Pays: United States
ID NLM: 101595366

Informations de publication

Date de publication:
09 01 2021
Historique:
received: 04 06 2020
accepted: 12 10 2020
pubmed: 15 10 2020
medline: 23 1 2021
entrez: 14 10 2020
Statut: ppublish

Résumé

despite being in the 5th month of pandemic, knowledge with respect to viral dynamics, infectivity and RT-PCR positivity continues to evolve. to analyse the SARS CoV-2 nucleic acid RT-PCR profiles in COVID-19 patients. it was a retrospective, observational study conducted at COVID facilities under AIIMS, New Delhi. patients admitted with laboratory confirmed COVID-19 were eligible for enrolment. Patients with incomplete details, or only single PCR tests were excluded. Data regarding demographic details, comorbidities, treatment received and results of SARS-CoV-2 RT-PCR performed on nasopharyngeal and oropharyngeal swabs, collected at different time points, was retrieved from the hospital records. a total of 298 patients were included, majority were males (75·8%) with mean age of 39·07 years (0·6-88 years). The mean duration from symptom onset to first positive RT-PCR was 4·7 days (SD 3·67), while that of symptom onset to last positive test was 17·83 days (SD 6·22). Proportions of positive RT-PCR tests were 100%, 49%, 24%, 8·7% and 20·6% in the 1st, 2nd, 3rd, 4th and >4 weeks of illness. A total of 12 symptomatic patients had prolonged positive test results even after 3 weeks of symptom onset. Age > = 60 years was associated with prolonged RT-PCR positivity (statistically significant). this study showed that the average period of PCR positivity is more than 2 weeks in COVID-19 patients; elderly patients have prolonged duration of RT-PCR positivity and requires further follow up.

Sections du résumé

BACKGROUND
despite being in the 5th month of pandemic, knowledge with respect to viral dynamics, infectivity and RT-PCR positivity continues to evolve.
AIM
to analyse the SARS CoV-2 nucleic acid RT-PCR profiles in COVID-19 patients.
DESIGN
it was a retrospective, observational study conducted at COVID facilities under AIIMS, New Delhi.
METHODS
patients admitted with laboratory confirmed COVID-19 were eligible for enrolment. Patients with incomplete details, or only single PCR tests were excluded. Data regarding demographic details, comorbidities, treatment received and results of SARS-CoV-2 RT-PCR performed on nasopharyngeal and oropharyngeal swabs, collected at different time points, was retrieved from the hospital records.
RESULTS
a total of 298 patients were included, majority were males (75·8%) with mean age of 39·07 years (0·6-88 years). The mean duration from symptom onset to first positive RT-PCR was 4·7 days (SD 3·67), while that of symptom onset to last positive test was 17·83 days (SD 6·22). Proportions of positive RT-PCR tests were 100%, 49%, 24%, 8·7% and 20·6% in the 1st, 2nd, 3rd, 4th and >4 weeks of illness. A total of 12 symptomatic patients had prolonged positive test results even after 3 weeks of symptom onset. Age > = 60 years was associated with prolonged RT-PCR positivity (statistically significant).
CONCLUSION
this study showed that the average period of PCR positivity is more than 2 weeks in COVID-19 patients; elderly patients have prolonged duration of RT-PCR positivity and requires further follow up.

Identifiants

pubmed: 33053181
pii: 5923555
doi: 10.1093/femspd/ftaa064
pmc: PMC7665504
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.

Auteurs

Bisakh Bhattacharya (B)

Department of Medicine, All India Institute of Medical Sciences, Medicine Office, 3rd floor, Teaching block, AIIMS, New Delhi, India.

Rohit Kumar (R)

Department of Medicine, All India Institute of Medical Sciences, Medicine Office, 3rd floor, Teaching block, AIIMS, New Delhi, India.

Ved Prakash Meena (VP)

Department of Medicine, All India Institute of Medical Sciences, Medicine Office, 3rd floor, Teaching block, AIIMS, New Delhi, India.

Manish Soneja (M)

Department of Medicine, All India Institute of Medical Sciences, Medicine Office, 3rd floor, Teaching block, AIIMS, New Delhi, India.

Amit Singh (A)

Department of Microbiology, Teaching block, 2nd floor, All India Institute of Medical Sciences, New Delhi, India.

Rojaleen Das (R)

Department of Microbiology, Teaching block, 2nd floor, All India Institute of Medical Sciences, New Delhi, India.

Ashit Xess (A)

Department of Microbiology, Teaching block, 2nd floor, All India Institute of Medical Sciences, New Delhi, India.

Nazneen Arif (N)

Department of Microbiology, Teaching block, 2nd floor, All India Institute of Medical Sciences, New Delhi, India.

Saurabh Vig (S)

Department of Onco-anesthesia and Palliative Medicine, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.

Vandana Rastogi (V)

Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.

Pavan Tiwari (P)

Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India.

Sushma Bhatnagar (S)

Department of Onco-anesthesia and Palliative Medicine, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.

Anant Mohan (A)

Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India.

Naveet Wig (N)

Department of Medicine, All India Institute of Medical Sciences, Medicine Office, 3rd floor, Teaching block, AIIMS, New Delhi, India.

Lalit Dar (L)

Department of Microbiology, Teaching block, 2nd floor, All India Institute of Medical Sciences, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH